Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Japanese phase II/III trial in osteoporosis meets primary endpoint

Dec. 15, 2011

Tarsa Therapeutics plans NDA submission for oral recombinant calcitonin

Dec. 15, 2011

New glimepiride formulation launched in Japan

Dec. 15, 2011

Acasti Pharma begins second phase II CaPre study

Dec. 15, 2011

Transition Therapeutics begins phase I TT-401 trial

Dec. 14, 2011

Repros Therapeutics reports topline data on Androxal in hypogonadism and type 2 diabetes

Dec. 14, 2011

Mochida out-licenses type 2 diabetes treatment candidates

Dec. 13, 2011

Gedeon Richter gains extended marketing rights for Esmya

Dec. 12, 2011

Unigene Laboratories regains worldwide rights to oral PTH program

Dec. 12, 2011

Nissan Chemical presents novel adiponectin receptor protein 1 agonists

Dec. 12, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...